Product Image

Contributor Information

  • Name Irene Leigh
  • Institute Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details

  • Tool name: Anti-Keratin 19 [LP2K]
  • Alternate names: 4 kDa keratin intermediate filament antibody, CK 19 antibody, CK-19 antibody, CK19 antibody, Cytokeratin 19 antibody, Cytokeratin-19 antibody, K19 antibody, K1C19_HUMAN antibody, K1CS antibody, Keratin 19 antibody, Keratin type I 4 kD antibody, Keratin type I 4kD antibody, Keratin type I cytoskeletal, 19 antibody, Keratin, type I cytoskeletal 19 antibody, Keratin type I 4 kd antibody, Keratin-19 antibody, KRT19 antibody, MGC15366 antibody
  • Clone: LP2K
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Molecular weight of the target: 40 kDa
  • Application: IHC ; WB
  • Strain: Balb/c
  • Description: Keratin 19 was first detected in squamous cell carcinoma lines and it is identifiable by its characteristically low molecular weight on SDS gels at 40 kD. It is generally regarded as being characteristic of simple epithelia such as intestine, kidney collecting ducts, gallbladder, mesothelium, and glandular secretory cells. Keratin 19 has unusually wide tissue distribution, and has been reported to be present, in significant quantities and under apparently normal conditions, in both stratified and squamous epithelia. Keratin 19 is a tumour marker used to establish poor prognosis in several types of carcinoma including hepatocellular and NSCL.
  • Immunogen: Sonicated cytoskeleton fractions (material insoluble in 1% Nonidet-P40(N-P40)) from SVK14 cells (SV40-transformed human neonatalkeratinocytes: 19)
  • Research area: Cancer; Cell biology
  • Myeloma used: Sp2/0-Ag14

  • For Research Use Only

Target Details

  • Target: Keratin 19
  • Target molecular weight: 40 kDa
  • Target background: Keratin 19 was first detected in squamous cell carcinoma lines and it is identifiable by its characteristically low molecular weight on SDS gels at 40 kD. It is generally regarded as being characteristic of simple epithelia such as intestine, kidney collecting ducts, gallbladder, mesothelium, and glandular secretory cells. Keratin 19 has unusually wide tissue distribution, and has been reported to be present, in significant quantities and under apparently normal conditions, in both stratified and squamous epithelia. Keratin 19 is a tumour marker used to establish poor prognosis in several types of carcinoma including hepatocellular and NSCL.

Application Details

  • Application: IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-Fibronectin [Fn-3]

#151098
Product Image

Anti-CD22 [To15]

#151792
Product Image

Anti-DNA [m17-ps-c7]

#157792

References

  • •  Bttger et al. 1995. Eur J Biochem. 231(2):475-85. PMID: 7543411.
  • •  Epitope mapping of monoclonal antibodies to keratin 19 using keratin fragments, synthetic peptides and phage peptide libraries.
  • •  Fridmacher et al. 1992. Development. 115(2):503-17. PMID: 1385062.
  • •  Differential expression of acidic cytokeratins 18 and 19 during sexual differentiation of the rat gonad.
  • •  Stasiak et al. 1989. J Invest Dermatol. 92(5):707-16. PMID: 2469734.
  • •  Keratin 19: predicted amino acid sequence and broad tissue distribution suggest it evolved from keratinocyte keratins.